Specifically, TP53 single-hit cases were more common in the blast <5% group, while TP53 double-hit cases dominated the >5% blast groups, with frequencies of 67%, 91% and 71% in the ≥5% to 9%, and ≥10% to 19%, and AML categories, respectively [3]. This evidence concerns the gene TP53 and acute myeloid leukemia.